Carbonic anhydrase inhibitors and their therapeutic potential

Abstract

Carbonic anhydrases (CAs, EC 4.2.1.1) are wide-spread zinc enzymes, present in archaeo- and eubacteria, algae, green plants and animals. Within these organisms CAs are encoded by three distinct, evolutionarily unrelated gene families: the α-CA, the β-CA and the γ-CA families, respectively. These enzymes are very efficient catalysts for the reversible hydration of CO₂ to bicarbonate; the α-CAs possess high versatility, being able to catalyse other hydrolytic processes. It is not known whether other reactions catalysed by CAs (than the hydration of CO₂/dehydration of HCO^-) may have physiological relevance in systems where these enzymes are present. CAs are inhibited primarily by two main classes of compounds: the metal complexing inorganic anions (e.g., cyanide, cyanate, thiocyanate, azide, hydrogensulphide etc.) and the unsubstituted sulphonamides possessing the general formula RSO₂NH₂ (R = aryl; hetaryl; perhaloalkyl). The first type of inhibitor was important for understanding in detail the catalytic and inhibitory mechanisms, whereas the second led to the development of several classes of pharmacological agents. Inhibitors of both types directly bind to the metal ion within the enzyme active site, either by substituting the zinc-bound H^-, or adding to the co-ordination sphere, leading thus to pentaco-ordinated Zn(II). Sulphonamide CA inhibitors (CAIs) are useful as diuretics, or in the treatment and prevention of a variety of diseases such as glaucoma, epilepsy, congestive heart failure, mountain sickness, gastric and duodenal ulcers, neurological disorders and osteoporosis among others, as well as diagnostic tools. Their applications are due to the wide distribution of the different α-CA isozymes (14 are presently known) in higher vertebrates, where they play important physiological functions related to respiration and transport of CO₂/HCO₃ between metabolising tissues and the lungs, pH and CO₂ homeostasis, electrolyte secretion in a variety of tissues/organs, and biosynthetic reactions, such as gluconeogenesis and ureagenesis, among others. CA activators have recently been described and their mechanism of action at molecular level elucidated. Such agents might be useful for developing therapies for the CA deficiency syndrome.

• antiglaucoma drugs
• anti-ulcer drugs
• carbonic anhydrase
• cerebrovasodilators
• diagnostic tools
• diuretics
• enzyme activator
• epilepsy
• isozymes I-XIV
• macular oedema
• neurological disorders
• osteoporosis
• sulphonamide
• tumour growth inhibition